Five grants totaling more than $4 million in funding were awarded to support clinical research projects investigating IBRANCE (palbociclib), an oral, first-in-class inhibitor of cyclin-dependent kinases
(CDKs) 4 and 6, in advanced breast cancer for 2015.
About Abemaciclib Cyclin-dependent kinases
play a key role in regulating cell cycle progression.
Kenpaullone impedes the action of proteins called cyclin-dependent kinases
, which affect nerve cell growth and many other cell functions.
Results from Western blotting indicated that Gyp inhibited the protein levels of cyclin D1 and E, cyclin-dependent kinases
cdk2 and cdk6 (Fig.
Abnormal expression of cyclin D1 and cyclin-dependent kinases
(CDKs) have been considered to be one of the most important factors in the tumourigenesis of various human malignancies.
Among the topics discussed are the QSAR computational model for identifying cyclin-dependent kinases
as a therapeutic target in lung cancer, molecular analysis of genetic risk factors for benign prostatic hyperplasia (BPH), and the relationship between obesity and cancer.
Washington, May 20 (ANI): In a new clinical trial, scientists have found that SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases
, is safe and could offer a potential clinical cure for advanced chronic lymphocytic leukemia (CLL).
p21WAF1 (p21) and p27KIP1 (p27) are both universal inhibitors of cyclin-dependent kinases
and can therefore influence cell cycle or tumor progression.
It prevents premature activation of cyclin E-cyclin-dependent kinase
2 in G1 and promotes the assembly and activation of D-type cyclin-dependent kinases
(Cdks) are proteins that are involved in the regulation of the cell cycle.
p2lWafl/Cipl is an inhibitor of cyclin-dependent kinases
involved in regulation of cell division and was the founding member of a family of functionally related kinase inhibitors (cycin-dependent kinase inhibitors; CKIs), now known to include p27, p28, p57, and DACAPO.
Dinaciclib is a pro-apoptotic inhibitor of cyclin-dependent kinases
being evaluated by Merck for the potential treatment of cancer.